BR112022009290A2 - Terapia para malignidades de células hematopoiéticas com o uso de células t geneticamente modificadas visando cd70 - Google Patents

Terapia para malignidades de células hematopoiéticas com o uso de células t geneticamente modificadas visando cd70

Info

Publication number
BR112022009290A2
BR112022009290A2 BR112022009290A BR112022009290A BR112022009290A2 BR 112022009290 A2 BR112022009290 A2 BR 112022009290A2 BR 112022009290 A BR112022009290 A BR 112022009290A BR 112022009290 A BR112022009290 A BR 112022009290A BR 112022009290 A2 BR112022009290 A2 BR 112022009290A2
Authority
BR
Brazil
Prior art keywords
genetically modified
malignities
therapy
hematopoietic cell
cells targeting
Prior art date
Application number
BR112022009290A
Other languages
English (en)
Portuguese (pt)
Inventor
Alexander Terrett Jonathan
Dequéant Mary-Lee
Will Matthias
Original Assignee
Crispr Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crispr Therapeutics Ag filed Critical Crispr Therapeutics Ag
Publication of BR112022009290A2 publication Critical patent/BR112022009290A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001138—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4232—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
BR112022009290A 2019-11-13 2020-11-13 Terapia para malignidades de células hematopoiéticas com o uso de células t geneticamente modificadas visando cd70 BR112022009290A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962934945P 2019-11-13 2019-11-13
US202063034510P 2020-06-04 2020-06-04
PCT/IB2020/060718 WO2021095009A1 (en) 2019-11-13 2020-11-13 Therapy for hematopoietic cell malignancies using genetically engineered t cells targeting cd70

Publications (1)

Publication Number Publication Date
BR112022009290A2 true BR112022009290A2 (pt) 2022-08-09

Family

ID=73554470

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022009290A BR112022009290A2 (pt) 2019-11-13 2020-11-13 Terapia para malignidades de células hematopoiéticas com o uso de células t geneticamente modificadas visando cd70

Country Status (11)

Country Link
US (1) US20220387571A1 (cg-RX-API-DMAC7.html)
EP (1) EP4058051A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023501590A (cg-RX-API-DMAC7.html)
KR (1) KR20220100912A (cg-RX-API-DMAC7.html)
CN (1) CN114845730A (cg-RX-API-DMAC7.html)
AU (1) AU2020384951A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022009290A2 (cg-RX-API-DMAC7.html)
CA (1) CA3158090A1 (cg-RX-API-DMAC7.html)
IL (1) IL292467A (cg-RX-API-DMAC7.html)
MX (1) MX2022005815A (cg-RX-API-DMAC7.html)
WO (1) WO2021095009A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
MX2022015586A (es) 2020-06-12 2023-03-15 Nkarta Inc Linfocitos citolíticos naturales modificados genéticamente para inmunoterapia de cáncer dirigida a cd70.
IL303269A (en) 2020-12-03 2023-07-01 Century Therapeutics Inc Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
US20220387488A1 (en) * 2021-05-12 2022-12-08 Crispr Therapeutics Ag Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies
US20230128917A1 (en) * 2021-09-14 2023-04-27 Crispr Therapeutics Ag Genetically engineered immune cells having a disrupted cd83 gene
CN117173092B (zh) * 2023-06-28 2024-04-09 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) 一种基于图像处理的鼻咽癌放疗方法及系统
WO2025193386A1 (en) 2024-03-13 2025-09-18 Caribou Biosciences, Inc. Treatment regimens for autoimmune disease with cd19-targeting engineered immune cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11466291B2 (en) * 2016-07-06 2022-10-11 Cellectis Sequential gene editing in primary immune cells
BR112019023608A2 (pt) * 2017-05-12 2020-05-26 Crispr Therapeutics Ag Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
MX2020008184A (es) * 2018-02-01 2020-09-22 Pfizer Receptores de antigeno quimericos dirigidos a cd70.
US20200063100A1 (en) * 2018-05-11 2020-02-27 Crispr Therapeutics Ag Methods and compositions for treating cancer

Also Published As

Publication number Publication date
MX2022005815A (es) 2022-08-10
CA3158090A1 (en) 2021-05-20
KR20220100912A (ko) 2022-07-18
EP4058051A1 (en) 2022-09-21
US20220387571A1 (en) 2022-12-08
IL292467A (en) 2022-06-01
WO2021095009A1 (en) 2021-05-20
CN114845730A (zh) 2022-08-02
AU2020384951A1 (en) 2022-05-19
AU2020384951A9 (en) 2023-06-29
JP2023501590A (ja) 2023-01-18

Similar Documents

Publication Publication Date Title
BR112022009204A2 (pt) Terapia de carcinoma de células renais (rcc) usando células t geneticamente manipuladas visando cd70
BR112021021843A2 (pt) Composições de proteína de fusão quimicamente projetada e métodos de uso das mesmas
CL2021002249A1 (es) Composiciones de partículas de sílice mesoporosa para administración viral
CL2019002717A1 (es) Receptores de unión a antígeno mejorados.
MX2022005815A (es) Terapia para neoplasias malignas de celulas hematopoyeticas utilizando linfocitos t modificados geneticamente que se dirigen a cd70.
MX2020012561A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiazepinona e inmunoterapeuticos y metodos de uso de las mismas.
BR112022009141A2 (pt) Terapia contra tumores sólidos cd70+ usando células t geneticamente manipuladas visando cd70
BR112021016984A2 (pt) Receptores de antígeno quimérico direcionados a dll3 e agentes de ligação
BR112014006176A8 (pt) Rna transcrito in vitro ou rna sintético, composição, método para gerar uma população de células t geneticamente modificadas por rna, e, uso de uma célula t geneticamente modificada
CL2018000270A1 (es) Constructos de anticuerpo para cd70 y cd3.
BR112018070636A2 (pt) método de tratamento de um sujeito humano que tem câncer, anticorpo, uso de um anticorpo, anticorpo para uso, combinação de um anticorpo, kit para uso no tratamento de câncer, composição farmacêutica, anticorpo biespecífico, método para tratamento de câncer, anticorpo biespecífico para uso e método de depleção de células t reguladoras em um tumor sólido em um sujeito
CO2019000946A2 (es) Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos
BR112021021542A2 (pt) Terapia celular alogênica de malignidades de células b com o uso de células t geneticamente modificadas que têm como alvo cd19
BR112017001183A2 (pt) tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
BR112018070676A2 (pt) construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos
MX2022001776A (es) Terapias de combinacion de inmuno oncologia con conjugados de il-2.
BR112019014986A2 (pt) anticorpo que alveja bcma e uso do mesmo
MX2017002205A (es) Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
BR112021024978A2 (pt) Composições engajadoras específicas para macrófagos e métodos de uso das mesmas
CO2017010190A2 (es) Terapias cd20, terapias cd22 y terapias de combinación con una célula que expresa un receptor quimérico de antígeno (car) de cd19
EP4643874A3 (en) Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
BR112019018863A8 (pt) Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos
MX2017003645A (es) Direccion de celulas citotoxicas con receptores quimericos para inmunoterapia adoptiva.
BR112017018770A2 (pt) redução da tolerância imunológica induzida por pd-l1
BR112021026382A2 (pt) Uso de células t de receptor de antígenos quimérico e inibidores de células nk para tratamento de câncer

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]